METHODS: The BSRBR-RA is a national registry for patients with RA receiving biologic treatments, including anti-TNF inhibitors (e.g., adalimumab) and non-anti-TNF biologics, designed to evaluate the long-term safety and effectiveness of these agents in clinical practice. The gene discussed is TNF; the disease is rheumatoid arthritis.